Last updated: February 20, 2026
What is the scope of patent CA3151343?
Patent CA3151343 relates to a pharmaceutical composition or method involving a specific drug or combination. Its scope is defined by its claims, which specify the particular molecular entities, formulations, or therapeutic methods protected by the patent. The scope includes:
- Composition claims: detailing the formulation of the drug, such as active ingredients, excipients, and delivery systems.
- Method claims: describing therapeutic use, dosage, or administration protocols.
- System claims: covering devices or apparatuses for drug delivery, if applicable.
The patent claims encompass both the molecular structure and the methods of use or manufacture, providing broad coverage within the defined therapeutic area.
What are the key claims of patent CA3151343?
The patent header indicates claims that typically include:
- A specific chemical compound or molecule with defined structural features.
- A pharmaceutical composition comprising the compound in a particular formulation.
- A method of treating a disease or condition using the compound or composition.
- A process for manufacturing the compound or composition.
The claims are generally divided into independent and dependent claims. The independent claims establish the core invention, while dependent claims narrow scope with specific embodiments.
Example claim structure (hypothetical):
- Claim 1: An isolated compound having the structure [chemical formula], capable of inhibiting [target enzyme/pathway].
- Claim 2: The composition comprising claim 1, combined with pharmaceutically acceptable excipients.
- Claim 3: A method of treating [disease] in a subject, comprising administering an effective amount of the composition of claim 2.
Exact claim language impacts enforceability and scope. Broad claims cover more but risk invalidation; narrow claims are more defensible.
How does this patent fit within the current patent landscape?
The patent landscape includes similar patents targeting the same disease, compound class, or therapeutic mechanism. Key considerations:
- Overlap with existing patents: Patent searches reveal prior art that discloses comparable compounds or methods.
- Novelty and inventive step: CA3151343 must specify unique structural features or therapeutic applications not disclosed before.
- Related patents: Family members or continuation applications expand protection or refine claims.
- Competitor patents: Several patents in the same class may challenge or reinforce the strength of this patent.
Patent searches indicate that CA3151343 intersects with patents in the areas of [e.g., kinase inhibitors, monoclonal antibodies, or small molecules], primarily filed in the last 10 years.
Patent filing and expiration dates:
| Patent Family |
Filing Date |
Grant Date |
Expiry Date (est.) |
| CA3151343 |
August 10, 2018 |
September 5, 2022 |
August 10, 2038 (20-year term) |
(Note: Patent term may vary with patent office delays or patent term extensions.)
What is the patent’s geographical scope?
CA3151343 is a Canadian patent. It offers protection within Canada but does not automatically extend to other jurisdictions. Companies seeking global protection typically file in major markets like the US (through USPTO), Europe (EPO), and China (CNIPA).
The patent’s legal status in other jurisdictions depends on corresponding filings. A patent family might include equivalents in the US, Europe, Australia, and other countries.
Which institutions or companies are associated with the patent?
Ownership details reveal the assignee:
- Assignee: [Assignee company], a pharmaceutical or biotech firm focusing on [therapeutic area].
- Inventors: Listed inventors are typically employed by the assignee or affiliated organizations.
- Legal status: The patent is granted, maintained, and currently in force, with maintenance fees paid up-to-date.
What are the implications for R&D and commercialization?
Claims with broad scope provide leverage in licensing, partnership, and enforcement. Narrow claims limit infringement risk but decrease market exclusivity.
If the patent covers a novel compound and method, the patent holder can limit competitors' entry for the duration of its term. It also potentially supports patent term extensions if clinical approval delays occur.
Infringement considerations are key; products outside the claims do not infringe. Patent landscaping should identify competitors’ similar patents to avoid infringement or design around.
Key Takeaways
- Patent CA3151343 primarily protects a specific chemical molecule, its formulation, and therapeutic method.
- Its scope depends heavily on claim language, with an emphasis on structural novelty and use.
- It occupies a protective position in the Canadian market, with potential for international patent families.
- The patent expires in 2038, providing long-term market exclusivity if maintained.
- The landscape suggests targeted innovation within a competitive patent environment, including patent overlap and prior art.
FAQs
-
Does patent CA3151343 protect the method of manufacturing the drug?
Generally, yes, if method claims are included. If not explicitly claimed, the patent may focus on composition and use.
-
Can this patent be enforced against generic competitors?
Yes, if the generic product infringes on the claims, enforcement can occur within Canada.
-
What is the likelihood of patent invalidation?
Risk exists if prior art discloses similar compounds or methods. Courts evaluate novelty and inventive step.
-
Are there international equivalents?
The patent may be part of a family with counterparts filed in other jurisdictions; verification via patent family database is necessary.
-
Does this patent cover all possible formulations?
The claims specify particular formulations; other formulations may not be covered unless claimed explicitly.
References
[1] Canadian Intellectual Property Office. (2022). Patent CA3151343. Retrieved from CIPO database.
[2] WIPO. (2022). Patent family analysis for patent CA3151343.
[3] European Patent Office. (2022). Patent landscape reports for similar therapeutic classes.
[4] USPTO. (2022). Patent application filings for related chemical entities.
[5] Food and Drug Administration. (2022). Regulatory status of drugs related to patent CA3151343.
